CD4 and hepatocellular carcinoma: Therefore, we designed the current prospective study with three years of follow-up to evaluate the modulation and predictive utility of specific circulating immune cell subsets, including CD4+ T cells (Th1, Th17 and Treg cells), CD8+ T cells, NK cells and NKT cells, and plasma cytokines in unresectable HCC patients who underwent TACE.